Patents by Inventor Hugh D. Riordan

Hugh D. Riordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6827940
    Abstract: A method of obtaining a pharmacologically active extract of the cell walls of Gram-positive bacteria is disclosed. The method involves the treatment of the bacteria with acid such that the immune-stimulating properties are enhanced. The extracts have immune stimulating and anti-tumor activities with no toxicity at effective doses. The final products are stable, water-soluble powders.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: December 7, 2004
    Assignee: Aidan Products, LLC
    Inventors: Neil H. Riordan, XiaoLong Meng, Hugh D. Riordan
  • Patent number: 6813009
    Abstract: Serum emission can be used as the first test to detect metabolic disorders in mammals. When changes in emission of the serum from patients with different pathological conditions were characterized, a difference was seen for patients with diseases such as cancer, thyroid disorder, arthritis, diabetes, coronary artery disease (CAD), hypertension, CFS (chronic fatigue syndrome), and fibromyalgia. The level of emission was enhanced or diminished and correlated with the level of energy metabolism and the level of metabolic rate. The method can also be used for risk assessment, to identify whether a treatment is working or to follow the course of a treatment, and to identify changes in energy levels due to stress, etc.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: November 2, 2004
    Assignee: The Center for the Improvement of Human Functioning, International, Inc.
    Inventors: Hugh D. Riordan, Paul Rillema, Nina Mikarova
  • Patent number: 6599538
    Abstract: A bindweed and buckwheat extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed and buckwheat extract requires minimal purification and produces a low toxicity anti-tumor and immuno-stimulating extract.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: July 29, 2003
    Assignee: The Center for the Improvement of Human Functioning, Int., Inc.
    Inventors: Xiaolong Meng, Hugh D. Riordan, Neil H. Riordan
  • Publication number: 20030137649
    Abstract: Serum emission can be used as the first test to detect metabolic disorders in mammals. When changes in emission of the serum from patients with different pathological conditions were characterized, a difference was seen for patients with diseases such as cancer, thyroid disorder, arthritis, diabetes, coronary artery disease (CAD), hypertension, CFS (chronic fatigue syndrome), and fibromyalgia. The level of emission was enhanced or diminished and correlated with the level of energy metabolism and the level of metabolic rate. The method can also be used for risk assessment, to identify whether a treatment is working or to follow the course of a treatment, and to identify changes in energy levels due to stress, etc.
    Type: Application
    Filed: September 18, 2001
    Publication date: July 24, 2003
    Inventors: Hugh D. Riordan, Paul Rillema, Nina Mikarova
  • Patent number: 6596322
    Abstract: A bindweed and buckwheat extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed and buckwheat extract requires minimal purification and produces a low toxicity anti-tumor and immunostimulating extract.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: July 22, 2003
    Assignee: The Center for the Improvement of Human Functioning, Int., Inc.
    Inventors: Xiaolong Meng, Hugh D. Riordan, Neil H. Riordan
  • Publication number: 20020176901
    Abstract: A bindweed and buckwheat extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed and buckwheat extract requires minimal purification and produces a low toxicity anti-tumor and immunostimulating extract.
    Type: Application
    Filed: January 25, 2002
    Publication date: November 28, 2002
    Inventors: Xiaolong Meng, Hugh D. Riordan, Neil H. Riordan
  • Publication number: 20020127284
    Abstract: A bindweed and buckwheat extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed and buckwheat extract requires minimal purification and produces a low toxicity anti-tumor and immuno-stimulating extract.
    Type: Application
    Filed: January 25, 2002
    Publication date: September 12, 2002
    Inventors: Xiaolong Meng, Hugh D. Riordan, Neil H. Riordan
  • Patent number: 6436411
    Abstract: Treatment of tumors, including their metastases, is described. Retrieved cytokines and other molecules from the growth medium of human monocytes stimulated ex vivo with gamma globulin, or other immune stimulators are employed for cancer therapy.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: August 20, 2002
    Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.
    Inventors: Neil H. Riordan, Hugh D. Riordan
  • Patent number: 6083510
    Abstract: A purified bindweed extract is used to inhibit the growth of tumor cells, inhibit the growth of blood vessels, and enhance immune function. The bindweed extract is prepared by removing toxic low molecular weight components of Convolvulus arvensis.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: July 4, 2000
    Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.
    Inventors: Xiaolong Meng, Hugh D. Riordan, Neil H. Riordan
  • Patent number: 5639787
    Abstract: A method of treating cancer in a patient by raising and maintaining the concentration of ascorbic acid, or ascorbate, in the patient's plasma to at least the level expected to be toxic to an in vitro culture of cells of the type of cancer being treated, the required plasma ascorbate levels being achieved and maintained using long term intravenous infusions of large amounts of ascorbate, with or without ascorbate cytotoxicity effectiveness enhancing or tumor site delivery and absorption enhancing agents.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: June 17, 1997
    Assignee: The Center for the Improvement of Human Functioning Int'l, Inc.
    Inventors: Neil H. Riordan, Hugh D. Riordan